These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4459738)

  • 1. Phase I-II evaluation of weekly mitomycin-C (NSC-26980) for patients with metastatic GI and breast malignancies.
    Hum GJ; Bogdon DL; Bateman JR
    Oncology; 1974; 30(3):236-43. PubMed ID: 4459738
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.
    van Oosterom AT; Powles TJ; Hamersma E; Smith IE; Engelsman E
    Eur J Cancer (1965); 1980; Suppl 1():275-6. PubMed ID: 6797825
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase I-II study of continuous 5-day infusion mitomycin-C.
    Yap HY; Valdivieso M; Blumenschein G; Hortobagyi G; Bedikian A
    Am J Clin Oncol; 1983 Feb; 6(1):109-12. PubMed ID: 6404154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy.
    Lopez M; Papaldo P; Di Lauro L; Barduagni M; Perno CF; Barduagni A
    Oncology; 1983; 40(4):244-7. PubMed ID: 6408547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.
    Sutow WW; Wilbur JR; Vietti TJ; Vuthibhagdee P; Fujimoto T; Watanabe A
    Cancer Chemother Rep; 1971 Jun; 55(3):285-9. PubMed ID: 4107239
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with mitomycin C (NSC-26980).
    Whittington RM; Close HP
    Cancer Chemother Rep; 1970 Jun; 54(3):195-8. PubMed ID: 4334088
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitomycin C therapy in advanced gastrointestinal cancer.
    Moertel CG; Reitemeier RJ; Hahn RG
    JAMA; 1968 Jun; 204(12):1045-8. PubMed ID: 5694750
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitomycin-C therapy in advanced gastrointestinal malignant tumours.
    Vaidya MP; Prasad CN; Roy SK; Singh HN
    Indian J Cancer; 1974 Sep; 11(3):255-61. PubMed ID: 4140845
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy.
    Denefrio JM; East DR; Troner MB; Vogel CL
    Cancer Treat Rep; 1978 Dec; 62(12):2113-5. PubMed ID: 751719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.
    Buroker TR; Kim PN; Baker LH; Ratanatharathron V; Wojtaszak B; Vaitkevicius VK
    Med Pediatr Oncol; 1978; 4(1):35-42. PubMed ID: 342890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers.
    Buroker T; Baker L; Correa J; Schwartz LA; Vailtkevicius VK
    Cancer Treat Rep; 1977; 61(3):463-7. PubMed ID: 326403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
    Hoskins PJ; McMurtrie E; Swenerton KD
    Am J Clin Oncol; 1990 Oct; 13(5):416-9. PubMed ID: 2220661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
    Garewal HS; Brooks RJ; Jones SE; Miller TP
    J Clin Oncol; 1983 Dec; 1(12):772-5. PubMed ID: 6422004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
    Meguro S; Nagata T; Yokoyama K; Chinen T; Yamazaki H; Kobayashi T; Isogai Y; Ogawa M
    Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of oral mitomycin C.
    Crooke ST; Henderson M; Samson M; Baker LH
    Cancer Treat Rep; 1976 Nov; 60(11):1633-6. PubMed ID: 1035507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
    Gagliano RG; Panettiere FJ; Haas CD; Baker L; Hewlett J; Stuckey WJ; O'Bryan RM; Bottomley R; Heilburn LK
    Cancer Clin Trials; 1981; 4(4):401-5. PubMed ID: 7318121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
    Fujii M; Murakami N; Matsuka Y; Ejiri T; Asano K
    Gan No Rinsho; 1983 Feb; 29(2):A-8, 129-32. PubMed ID: 6308301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin].
    Toda K; Asaishi K; Okazaki A; Okazaki Y; Okazaki M; Ebata T; Totsuka M; Hayasaka H; Sato N; Narimatsu E
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2298-304. PubMed ID: 2934023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin is active against refractory germ-cell tumors. A phase II study.
    Hoskins P; Coppin CM; Murray N
    Am J Clin Oncol; 1990 Feb; 13(1):35-8. PubMed ID: 2154922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
    Muhonen TT; Wiklund TA; Blomqvist CP; Pyrhönen SO
    Eur J Cancer; 1992; 28A(12):1974-6. PubMed ID: 1419293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.